MX338887B - Alcoxipirazoles como activadores de guanilato ciclasa soluble. - Google Patents
Alcoxipirazoles como activadores de guanilato ciclasa soluble.Info
- Publication number
- MX338887B MX338887B MX2015002807A MX2015002807A MX338887B MX 338887 B MX338887 B MX 338887B MX 2015002807 A MX2015002807 A MX 2015002807A MX 2015002807 A MX2015002807 A MX 2015002807A MX 338887 B MX338887 B MX 338887B
- Authority
- MX
- Mexico
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- compounds
- cyclase activators
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención se refiere a los compuestos de la Fórmula (I) (ver Fórmula) y a sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, procesos para preparar estos compuestos e intermediarios útiles en estos procesos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697899P | 2012-09-07 | 2012-09-07 | |
PCT/US2013/057826 WO2014039434A1 (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015002807A MX2015002807A (es) | 2015-05-15 |
MX338887B true MX338887B (es) | 2016-05-04 |
Family
ID=49170904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002807A MX338887B (es) | 2012-09-07 | 2013-09-03 | Alcoxipirazoles como activadores de guanilato ciclasa soluble. |
Country Status (38)
Country | Link |
---|---|
US (2) | US8906904B2 (es) |
EP (1) | EP2892891B1 (es) |
JP (1) | JP5970134B2 (es) |
KR (1) | KR101692707B1 (es) |
CN (1) | CN104619695B (es) |
AP (1) | AP2015008231A0 (es) |
AR (1) | AR092869A1 (es) |
AU (1) | AU2013312931B2 (es) |
BR (1) | BR112015004529B1 (es) |
CA (1) | CA2880494C (es) |
CL (2) | CL2015000255A1 (es) |
CY (1) | CY1122610T1 (es) |
DK (1) | DK2892891T3 (es) |
EA (1) | EA027244B1 (es) |
EC (1) | ECSP15012804A (es) |
ES (1) | ES2748798T3 (es) |
GE (1) | GEP20176631B (es) |
HK (1) | HK1210164A1 (es) |
HR (1) | HRP20191755T1 (es) |
HU (1) | HUE046996T2 (es) |
IL (1) | IL236987A (es) |
LT (1) | LT2892891T (es) |
MA (1) | MA37891B1 (es) |
MD (1) | MD4425C1 (es) |
MX (1) | MX338887B (es) |
NZ (1) | NZ703989A (es) |
PE (1) | PE20151001A1 (es) |
PH (1) | PH12015500457B1 (es) |
PL (1) | PL2892891T3 (es) |
PT (1) | PT2892891T (es) |
RS (1) | RS59394B1 (es) |
SG (2) | SG10201510668UA (es) |
SI (1) | SI2892891T1 (es) |
TN (1) | TN2015000054A1 (es) |
TW (1) | TWI586661B (es) |
UA (1) | UA115881C2 (es) |
UY (1) | UY35012A (es) |
WO (1) | WO2014039434A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2880494C (en) * | 2012-09-07 | 2021-09-21 | Boehringer Ingelheim International Gmbh | Alkoxy pyrazoles as soluble guanylate cyclase activators |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
WO2016014463A1 (en) * | 2014-07-22 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
US10316020B2 (en) | 2015-12-18 | 2019-06-11 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
JP7237823B2 (ja) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Sgcアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
JP2021523201A (ja) | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | 神経線維感作に関連する疾患を治療するための1,3−チアゾール−2−イル置換ベンズアミド |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
EP3820470A1 (en) | 2018-07-12 | 2021-05-19 | Boehringer Ingelheim International GmbH | Alkoxy pyrazoles as soluble guanylate cyclase activators |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
CN112079712B (zh) * | 2020-09-18 | 2022-12-13 | 江苏美迪克化学品有限公司 | 一种对乙烯基水杨酸的制备方法 |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
TW202402274A (zh) | 2022-03-21 | 2024-01-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療門脈高壓之可溶性鳥苷酸環化酶活化劑 |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
MXPA03004308A (es) | 2000-11-22 | 2003-08-19 | Visx Inc | Dispositivo de colocacion, accionado por la temperatura, para elementos opticos no lineales. |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
RU2005119173A (ru) * | 2002-12-20 | 2006-02-27 | Фармация Корпорейшн (Us) | Ациклические пиразольные соединения |
EP1906957A1 (en) | 2005-07-18 | 2008-04-09 | Bayer HealthCare AG | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
BRPI0811581A2 (pt) * | 2007-05-12 | 2014-12-09 | Bayer Schering Pharma Ag | Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos |
KR20100059952A (ko) | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
ES2527948T3 (es) | 2007-10-05 | 2015-02-02 | Sanofi-Aventis Deutschland Gmbh | Uso de N-fenilamidas de ácido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
TW200938529A (en) * | 2007-12-03 | 2009-09-16 | Smithkline Beecham Corp | Compounds |
EP2264017A4 (en) * | 2008-04-04 | 2011-07-27 | Takeda Pharmaceutical | Heterocyclic derivative and its use |
WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
KR20110117655A (ko) | 2009-01-17 | 2011-10-27 | 바이엘 파마 악티엔게젤샤프트 | 발기 부전의 치료를 위한 sgc 자극제 또는 sgc 활성화제와 pde5 억제제의 조합물 |
BRPI1008793A2 (pt) | 2009-02-26 | 2016-03-08 | Merck Sharp & Dohme | composto, uso de um composto, e, composição farmacêutica |
CN102770133A (zh) * | 2010-02-05 | 2012-11-07 | 拜耳知识产权有限责任公司 | 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂 |
WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
CA2800709C (en) * | 2010-05-26 | 2017-04-04 | Claudia Hirth-Dietrich | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc) |
EP2585055A1 (de) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
CA2880494C (en) * | 2012-09-07 | 2021-09-21 | Boehringer Ingelheim International Gmbh | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2013
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en active Application Filing
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
-
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457B1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
- 2015-11-06 HK HK15110980.4A patent/HK1210164A1/xx unknown
-
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
-
2019
- 2019-09-26 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
PH12017500111A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
MD20140002A2 (ro) | Indazoli | |
WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
PH12015501452A1 (en) | Novel quinolone derivatives | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
PH12015500063A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
IN2013DN02555A (es) | ||
MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
JO2851B1 (en) | 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof. | |
TN2013000122A1 (en) | Oxadiazole inhibitors of leukotriene production | |
TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production | |
TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |